JP6752874B2 - 筋萎縮性側索硬化症を治療するためのビオチン - Google Patents

筋萎縮性側索硬化症を治療するためのビオチン Download PDF

Info

Publication number
JP6752874B2
JP6752874B2 JP2018500860A JP2018500860A JP6752874B2 JP 6752874 B2 JP6752874 B2 JP 6752874B2 JP 2018500860 A JP2018500860 A JP 2018500860A JP 2018500860 A JP2018500860 A JP 2018500860A JP 6752874 B2 JP6752874 B2 JP 6752874B2
Authority
JP
Japan
Prior art keywords
biotin
pharmaceutical composition
composition according
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018500860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512451A5 (enExample
JP2018512451A (ja
Inventor
フレデリク、セデル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medday Pharmaceuticals
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6752874(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of JP2018512451A publication Critical patent/JP2018512451A/ja
Publication of JP2018512451A5 publication Critical patent/JP2018512451A5/ja
Application granted granted Critical
Publication of JP6752874B2 publication Critical patent/JP6752874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
JP2018500860A 2015-03-26 2016-03-25 筋萎縮性側索硬化症を治療するためのビオチン Expired - Fee Related JP6752874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305437.4 2015-03-26
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (3)

Publication Number Publication Date
JP2018512451A JP2018512451A (ja) 2018-05-17
JP2018512451A5 JP2018512451A5 (enExample) 2019-04-25
JP6752874B2 true JP6752874B2 (ja) 2020-09-09

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018500860A Expired - Fee Related JP6752874B2 (ja) 2015-03-26 2016-03-25 筋萎縮性側索硬化症を治療するためのビオチン

Country Status (24)

Country Link
US (2) US10357480B2 (enExample)
EP (2) EP3072513A1 (enExample)
JP (1) JP6752874B2 (enExample)
KR (1) KR20170131543A (enExample)
CN (2) CN111973592A (enExample)
AU (1) AU2016238759B2 (enExample)
BR (1) BR112017020408A2 (enExample)
CA (1) CA2980660A1 (enExample)
CY (1) CY1122374T1 (enExample)
DK (1) DK3273957T3 (enExample)
EA (1) EA034394B1 (enExample)
ES (1) ES2748354T3 (enExample)
HR (1) HRP20191491T1 (enExample)
HU (1) HUE046116T2 (enExample)
IL (1) IL254619B (enExample)
LT (1) LT3273957T (enExample)
MA (1) MA41809B1 (enExample)
ME (1) ME03567B (enExample)
PL (1) PL3273957T3 (enExample)
PT (1) PT3273957T (enExample)
RS (1) RS59149B1 (enExample)
SI (1) SI3273957T1 (enExample)
SM (1) SMT201900548T1 (enExample)
WO (1) WO2016151132A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
US12458607B2 (en) * 2018-12-11 2025-11-04 Myospots Australia Pty Ltd Adhesive pad
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
EP4225327A4 (en) * 2020-10-09 2024-10-16 TX Medic AB TREATMENT OF MUSCLE ATROPHY WITH DEXTRAN SULFATE
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
PL377612A1 (pl) 2002-09-27 2006-02-06 Biogen Idec Ma Inc. Terapie przewlekłej zapalnej polineuropatii demielinizacyjnej z użyciem interferonu-ß
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
US10654916B2 (en) * 2011-04-21 2020-05-19 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
WO2013010015A2 (en) * 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
US9789092B2 (en) 2013-04-29 2017-10-17 Assistance Publique—Hopitaux de Paris Biotin for use in treating X-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
CY1122374T1 (el) 2021-01-27
MA41809B1 (fr) 2019-12-31
HUE046116T2 (hu) 2020-02-28
ES2748354T3 (es) 2020-03-16
SMT201900548T1 (it) 2019-11-13
US20180125825A1 (en) 2018-05-10
SI3273957T1 (sl) 2019-11-29
BR112017020408A2 (pt) 2018-06-05
LT3273957T (lt) 2019-11-11
IL254619B (en) 2020-03-31
EP3273957A1 (en) 2018-01-31
EP3273957B1 (en) 2019-08-14
IL254619A0 (en) 2017-11-30
AU2016238759A1 (en) 2017-10-05
CN107405335A (zh) 2017-11-28
CN111973592A (zh) 2020-11-24
CA2980660A1 (en) 2016-09-29
PL3273957T3 (pl) 2020-01-31
JP2018512451A (ja) 2018-05-17
PT3273957T (pt) 2019-09-18
NZ735528A (en) 2021-09-24
EA034394B1 (ru) 2020-02-04
US10357480B2 (en) 2019-07-23
EP3072513A1 (en) 2016-09-28
KR20170131543A (ko) 2017-11-29
ME03567B (me) 2020-07-20
MA41809A (fr) 2018-01-30
HRP20191491T1 (hr) 2019-11-15
EA201792124A1 (ru) 2018-04-30
WO2016151132A1 (en) 2016-09-29
AU2016238759B2 (en) 2020-08-06
RS59149B1 (sr) 2019-09-30
US20190314342A1 (en) 2019-10-17
DK3273957T3 (da) 2019-11-11

Similar Documents

Publication Publication Date Title
JP6752874B2 (ja) 筋萎縮性側索硬化症を治療するためのビオチン
AU2013295370B2 (en) Use of biotin for the treatment of multiple sclerosis
KR20070086507A (ko) 다발성 경화증, 정서 불안정 및 가성구 정동 치료를 위한1-아미노시클로헥산 유도체
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
JP7352542B2 (ja) 運動失調を処置するためのリルゾールプロドラッグの使用
CN114146088A (zh) 用于治疗神经精神类障碍的组合物及方法
KR20250075589A (ko) 인지 장애를 치료하기 위한 사일로이노시톨 및 비타민 d 및/또는 다른 비타민 또는 유효 성분의 병용 치료
CN111542314A (zh) 神经退行性疾病的治疗剂
US9789092B2 (en) Biotin for use in treating X-linked adrenoleukodystrophy
EP4228646A1 (en) Treatment of cognitive impairment with a cns-penetrant sgc stimulator
HK1243938B (en) Biotin for treating demyelinating neuropathies
HK1243938A1 (en) Biotin for treating demyelinating neuropathies
NZ735528B2 (en) Biotin for treating demyelinating neuropathies
Beckett et al. Antiepileptics
HK40037184A (en) Use of riluzole prodrugs to treat ataxias

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200819

R150 Certificate of patent or registration of utility model

Ref document number: 6752874

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees